Imperial College London

Bryony Simmons

Faculty of MedicineDepartment of Medicine

Research Assistant







Medical SchoolSt Mary's Campus





Bryony is a PhD candidate jointly between the Division of Infectious Diseases and the Centre for Health Economics, Policy, and Innovation (CHEPI) at Imperial College Business School.

Her research focuses on impact evaluation of policies to improve access to essential medicines in low- and middle-income countries. She has focused largely on access to high-cost hepatitis C medicines in these settings. Her PhD is supervised by Prof Graham Cooke (Division of Infectious Diseases) and Dr Marisa Miraldo (Imperial College Business School).

Bryony holds a Master’s of Public Health (Global Health) from Imperial College London and a Master’s in Natural Sciences from University College London. Bryony previously worked for the Clinton Health Access Initiative (Rwanda) on the viral hepatitis programme and has provided statistical support for clinical studies.

Selected Publications

Journal Articles

Cooke GS, Andrieux-Meyer I, Applegate TL, et al., 2019, Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission, The Lancet Gastroenterology and Hepatology, Vol:4, ISSN:2468-1253, Pages:135-184

Umutesi J, Simmons B, Makuza JD, et al., 2017, Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda., BMC Infectious Diseases, Vol:17, ISSN:1471-2334

Simmons B, Saleem J, Hill A, et al., 2016, Risk of late relapse or reinfection with Hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis, Clinical Infectious Diseases, Vol:62, ISSN:1537-6591, Pages:683-694

Simmons B, Saleem J, Heath K, et al., 2015, Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response, Clinical Infectious Diseases, Vol:61, ISSN:1537-6591, Pages:730-740

Hill A, Khoo S, Fortunak J, et al., 2014, Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries, Clinical Infectious Diseases, Vol:58, ISSN:1058-4838, Pages:928-936

More Publications